Sexual evaluation and treatment of ageing males with haemophilia

Haemophilia

Volumn 17, Issue 6, 2011, Pages 875-883

  Bar Chama, N ^a   Snyder, S ^a   Aledort, L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Ageing; Erectile dysfunction; Haemophilia; Sexual dysfunction; Sexuality

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; COCAINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN; SEROTONIN UPTAKE INHIBITOR;

ADDISON DISEASE; AGING; ALCOHOL CONSUMPTION; ANDROGEN DEFICIENCY; ANXIETY DISORDER; ARTHRALGIA; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; CUSHING SYNDROME; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EJACULATION DISORDER; ENDOCRINE DISEASE; ERECTILE DYSFUNCTION; HEMOCHROMATOSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPROLACTINEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOGONADISM; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; LIVER CIRRHOSIS; MOOD DISORDER; NERVE INJURY; NEUROLOGIC DISEASE; PENIS ERECTION; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PREMATURE EJACULATION; PRIORITY JOURNAL; PUDENDAL NERVE; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SPINAL CORD INJURY; SPINE DISEASE; TOBACCO; VASCULAR DISEASE; ADULT; AGED; MALE; MENTAL DISEASE; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOSEXUAL DISORDER; REVIEW;

ADULT; AGED; AGING; HEMOPHILIA A; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; VASCULAR DISEASES;

EID: 84857970013     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02507.x     Document Type: Article

References (90)

1. Aversa A, Bruzziches R, Francomano D, Natali M, Gareri P, Spera G. Endothelial dysfunction and erectile dysfunction in the aging man. Int J Urol 2010; 17: 38-47.
2. O'Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: the Massachusetts Male Aging Study (1987-2004). Exp Gerontol 2004; 39: 975-84.
3. Gianotten WL, Heijnen L. Haemophilia, aging and sexuality. Haemophilia 2009; 15: 55-62.
4. Collazos J. Sexual dysfunction in the highly active antiretroviral therapy era. AIDS Rev 2007; 9: 237-45.
5. Rosenberg MT. Diagnosis and management of erectile dysfunction in the primary care setting. Int J Clin Pract 2007; 61: 1198-208.
6. NIH Consensus Development Program on Impotence. Impotence. National Institutes of Health Consensus Development Conference Statement. JAMA 1993; 270: 83-90.
7. Irekpita E, Salami TA. Erectile dysfunction and its relationship with cardiovascular risk factors and disease. Saudi Med J 2009; 30: 184-90.
8. Kolodny L. Erectile dysfunction and vascular disease. What is the connection? Postgrad Med 2003; 114: 30-4.
9. Tamler R. Diabetes, obesity and erectile dysfunction. Gend Med 2009; 6(Suppl 1): 4-16.
10. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996-3002.
11. Montorsi F, Briganti A, Salonia A et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360-4; discussion 4-5.
12. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 2341-5.
13. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010; 7: 46-56.
14. Esposito K, Giugliano F, Martedi E et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005; 28: 1201-3.
15. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997; 9: 123-6.
16. Guay AT. ED2: erectile dysfunction = endothelial dysfunction. Endocrinol Metab Clin North Am 2007; 36: 453-63.
17. Shindel AW, Kishore S, Lue TF. Drugs designed to improve endothelial function: effects on erectile dysfunction. Curr Pharm Des 2008; 14: 3758-67.
18. Cooke JP. The endothelium: a new target for therapy. Vasc Med 2000; 5: 49-53.
19. Tamler R, Bar-Chama N. Assessment of endothelial function in the patient with erectile dysfunction: an opportunity for the urologist. Int J Impot Res 2008; 20: 370-7.
20. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-3.
21. Rosendaal FR, Varekamp I, Smit C et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71: 71-6.
22. Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briet E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123: 823-7.
23. Baarslag MA, Rafi S, Kruip MJHA, Peters M, Kamphuisen PW. The inverse association between hemophilia and cariovascular mortality is not explained by differences in cardiovascular risk profile. J Thromb Haemost 2009; 7: 812 (Abstract PP-WE-548).
24. Foley CJ, Nichols L, Jeong K, Moore CG, Ragni MV. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost 2010; 8: 208-11.
25. Zwiers M, Lijfering WM, Meijer K, Lefrandt JD, Smit AJ, van der Meer J. Hemophilia A and cardiovascular events: a case series. J Thromb Haemost 2009; 7. (Abstract PP-WE-554).
26. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Eng J Med 2007; 356: 1723-35.
27. van Leth F, Phanuphak P, Stroes E et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Medi 2004; 1: e19.
28. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-76.
29. Theodoraki A, Bouloux PM. Testosterone therapy in men. Menopause Int 2009; 15: 87-92.
30. Stanworth RD, Jones TH. Testosterone for the aging male; current evidence and recommended practice. Clin Interv Aging 2008; 3: 25-44.
31. Safarinejad MR, Hosseini SY. Erectile dysfunction: clinical guidelines (2). Urol J 2004; 1: 227-39.
32. The Endocrine Society. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-59.
33. Nieschlag E, Swerdloff R, Behre HM et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005; 8: 56-8.
34. Safarinejad MR, Hosseini S. Erectile dysfunction: clinical guidelines (1). Urol J 2004; 1: 133-47.
35. Danoff A, Khan O, Wan DW et al. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am J Gastroenterol 2006; 101: 1235-43.
36. Lamba H, Goldmeier D, Mackie NE, Scullard G. Antiretroviral therapy is associated with sexual dysfunction and with increased serum oestradiol levels in men. Int J STD AIDS 2004; 15: 234-7.
37. Levy J. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. Br J Vasc Dis 2002; 2: 278-80.
38. Soucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The hemophilia surveillance system project investigators. Blood 2000; 96: 437-42.
39. Kulkarni R, Soucie JM, Evatt B. Renal disease among males with haemophilia. Haemophilia 2003; 9: 703-10.
40. Rao TK. Human immunodeficiency virus infection and renal failure. Infect Dis Clin North Am 2001; 15: 833-50.
41. Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course and management. Clin Infect Dis 2001; 33: 115-9.
42. United States Renal Data System. Executive United States Renal Data System 1999 Annual Data Report. Am J Kidney Dis 1999; 34: S9-19.
43. National Institutes of Diabetes and Digestive and Kidney Disease. Chronic hepatitis C: current disease management. Available at: Assessed June 14, 2010.
44. Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94: 746-52.
45. Thabut D, Le Calvez S, Thibault V et al. Hepatitis C in 6, 865 patients 65yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006; 101: 1260-7.
46. Centers for Disease Control and Prevention. Summary report of UDC national activity. Treatment/clinical characteristics (hemophilia). Available at: Accessed July 15, 2010.
47. Pergantou H, Matsinos G, Papadopoulos A, Platokouki H, Aronis S. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 2006; 12: 241-7.
48. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12(Suppl 3): 117-21.
49. Fakhari A, Dolatkhan R. Psychiatric disorders in hemophilic patients. Priory Medi J Available at: Accessed February 11, 2010.
50. American Psychiatric Association. Major Depressive Disorder. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision. Washington, DC: American Psychiatric Assocation, 2000.
51. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
52. Thase ME, Reynolds CF 3rd, Glanz LM et al. Nocturnal penile tumescence in depressed men. Am J Psychiatry 1987; 144: 89-92.
53. Thase ME, Reynolds CF 3rd, Jennings JR et al. Diminished nocturnal penile tumescence in depression: a replication study. Biol Psychiatry 1992; 31: 1136-42.
54. Kennedy SH, Rizvi S. Sexual dysfunction, depression and the impact of antidepressants. J Clin Psychopharmacol 2009; 29: 157-64.
55. Seidman SN, Roose SP. The relationship between depression and erectile dysfunction. Curr Psychiatry Rep 2000; 2: 201-5.
56. Segraves RT, Balon R. Sexual Pharmacology: Fast Facts. New York, NY: W.W. Norton & Company, Inc., 2003.
57. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002; 3: 377-84.
58. Kraus MR, Schafer A, Bentink T et al. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression? J Endocrinol 2005; 185: 345-52.
59. Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry 2009; 43: 795-808.
60. Segraves R. Recognising and reversing sexual side effects of medication. In: Levine SC, Risen C, Althof S eds. Handbook of Clinical Sexuality for Mental Health Professionals. New York, NY: Brunner-Routledge, 2003: 377-92.
61. Segraves RT. Sexual dysfunction associated with antidepressant therapy. Urol Clin North Am 2007; 34: 575-9.vii.
62. Wylie K, Kenney G. Sexual dysfunction and the ageing male. Maturitas 2010; 65: 23-7.
63. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
64. O'Leary MP, Fowler FJ, Lenderking WR et al. A brief male sexual function inventory for urology. Urology 1995; 46: 697-706.
65. Liebman HA, Rosenwald-Zuckerman T, Retzios A, Yasmin S, Kasper CK. Kinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacement. Haemophilia 1999; 5: 174-80.
66. Derby CA, Araujo AB, Johannes CB, Feldman HA, McKinlay JB. Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study. Int J Impot Res 2000; 12: 197-204.
67. Lue TF. Erectile dysfunction. N Eng J Med 2000; 342: 1802-13.
68. Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int 2001; 87: 838-45.
69. Qaseem A, Snow V, Denberg TD et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the american college of physicians. Ann Intern Med 2009; 151: 639-49.
70. Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-6.
71. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-404.
72. Hellstrom WJ, Gittelman M, Karlin G et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-71.
73. Giannitsas K, Konstantinopoulos A, Patsialas C, Perimenis P. Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. Patient Prefer Adherence 2008; 2: 149-55.
74. Aversa A, Vitale C, Volterrani M et al. Chronic administration of Sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 2008; 25: 37-44.
75. Sivalingam S, Hashim H, Schwaibold H. An overview of the diagnosis and treatment of erectile dysfunction. Drugs 2006; 66: 2339-55.
76. Tsertsvadze A, Fink HA, Yazdi F et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009; 151: 650-61.
77. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007; 19: 200-7.
78. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50: 99-107.
79. Fazio L, Brock G. Erectile dysfunction: management update. Can Med Assoc J 2004; 170: 1429-37.
80. Gray PB, Singh AB, Woodhouse LJ et al. Dose-dependent effects of testosterone on sexual function, mood and visuospatial cognition in older men. J Clin Endocrinol Metab 2005; 90: 3838-46.
81. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007; 4: 497-501.
82. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005; 173: 530-2.
83. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658-63.
84. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003; 88: 2673-81.
85. MUSE (alprostadil) Urethral Suppository [package insert]. Mountain View, CA: Vivus, Inc., 2003.
86. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606-13.
87. Segraves RT, Kavoussi R, Hughes AR et al. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2000; 20: 122-8.
88. Sadovsky R, Dunn M, Grobe BM. Erectile dysfunction: the primary care practitioner's view. Am J Manag Care 1999; 5: 333-41.quiz 42-3.
89. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder? Eur Urol 2003; 44: 352-4.
90. Guay AT. Relation of endothelial cell function to erectile dysfunction: implications for treatment. Am J Cardiol 2005; 96: 52M-6M.